ABILIFY MAINTENA KIT Drug Patent Profile

When do Abilify Maintena Kit patents expire, and what generic alternatives are available?

Abilify Maintena Kit is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in thirty countries.

The generic ingredient in ABILIFY MAINTENA KIT is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abilify Maintena Kit

A generic version of ABILIFY MAINTENA KIT was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ABILIFY MAINTENA KIT

International Patents:	44
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	125
Clinical Trials:	9
Patent Applications:	4,536
Drug Prices:	Drug price information for ABILIFY MAINTENA KIT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABILIFY MAINTENA KIT
DailyMed Link:	ABILIFY MAINTENA KIT at DailyMed

See drug prices for ABILIFY MAINTENA KIT

Recent Clinical Trials for ABILIFY MAINTENA KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Otsuka Beijing Research Institute	Phase 1
Chonbuk National University Hospital	Phase 4
Otsuka Pharmaceutical Co., Ltd.	Phase 4

See all ABILIFY MAINTENA KIT clinical trials

Paragraph IV (Patent) Challenges for ABILIFY MAINTENA KIT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ABILIFY MAINTENA KIT	Extended-release Injectable Suspension	aripiprazole	300 mg/vial and 400 mg/vial	202971	1	2021-12-20

US Patents and Regulatory Information for ABILIFY MAINTENA KIT

ABILIFY MAINTENA KIT is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	11,344,547
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	11,648,347		Y
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-002	Feb 28, 2013		RX	Yes	Yes	11,648,347		Y
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	11,400,087
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014		RX	Yes	Yes	10,980,803

Expired US Patents for ABILIFY MAINTENA KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-002	Feb 28, 2013	8,338,428
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014	7,807,680
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-002	Feb 28, 2013	5,006,528*PED
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-004	Sep 29, 2014	8,338,427
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-003	Sep 29, 2014	8,993,761

EU/EMA Drug Approvals for ABILIFY MAINTENA KIT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)	aripiprazole	EMEA/H/C/003803Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-30
Otsuka Pharmaceutical Netherlands B.V.	Abilify	aripiprazole	EMEA/H/C/000471Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	no	no	no	2004-06-04
Otsuka Pharmaceutical Netherlands B.V.	Abilify Maintena	aripiprazole	EMEA/H/C/002755Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.	Authorised	no	no	no	2013-11-14
Accord Healthcare S.L.U.	Aripiprazole Accord	aripiprazole	EMEA/H/C/004021Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-11-15
Zentiva, k.s.	Aripiprazole Zentiva	aripiprazole	EMEA/H/C/003899Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-25

International Patents for ABILIFY MAINTENA KIT

See the table below for patents covering ABILIFY MAINTENA KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1091725	ARIPIPRAZOLE INJECTABLE SUSPENSION
Taiwan	201309294	Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
Norway	20081633
Germany	68925405
Japan	4614870

Supplementary Protection Certificates for ABILIFY MAINTENA KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	PA2014020	Lithuania		PRODUCT NAME: ARIPIPRAZOLUM; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119
0367141	C300161	Netherlands		PRODUCT NAME: ARIPIPRAZOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/276/001-005;006-010;011-015;016-020 20040604
1675573	C20140014 00322	Estonia		PRODUCT NAME: ARIPIPRASOOL;REG NO/DATE: K(2013)8163 (LOPLIK) 19.11.2013
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115

ABILIFY MAINTENA KIT Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ABILIFY MAINTENA KIT, a long-acting injectable antipsychotic, demonstrates a mature market presence characterized by established sales, ongoing patent challenges, and a dynamic competitive landscape. Its financial trajectory is influenced by generic competition, lifecycle management strategies, and ongoing clinical utility.

What is the core therapeutic indication and mechanism of action for ABILIFY MAINTENA KIT?

ABILIFY MAINTENA KIT (aripiprazole lauroxil) is indicated for the treatment of schizophrenia in adults and as an adjunctive treatment for depression in adults. The drug is a long-acting injectable prodrug of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist and a serotonin 5-HT2A receptor antagonist. This mechanism of action is believed to modulate dopaminergic and serotonergic systems, thereby reducing psychotic symptoms and improving mood. The long-acting injectable formulation aims to improve treatment adherence by providing sustained therapeutic levels over a specified dosing interval.

Who are the key manufacturers and developers of ABILIFY MAINTENA KIT?

Otsuka Pharmaceutical Co., Ltd. is the primary developer and marketer of ABILIFY MAINTENA KIT. Bristol Myers Squibb previously held co-marketing rights in certain territories but these arrangements have evolved. The intellectual property landscape surrounding ABILIFY MAINTENA KIT is complex, involving patents held by Otsuka and potential challenges from generic manufacturers.

What is the patent status and litigation history for ABILIFY MAINTENA KIT?

The patent landscape for ABILIFY MAINTENA KIT is a critical factor influencing its market exclusivity and future financial performance. The primary U.S. patent covering the formulation and method of use is U.S. Patent No. 8,557,804. This patent has faced numerous challenges from generic manufacturers seeking to introduce their own versions of aripiprazole lauroxil.

Several Paragraph IV patent certifications have been filed by generic companies, initiating patent litigation proceedings. These litigations typically revolve around allegations of patent infringement and include counterarguments of patent invalidity or non-infringement. The outcome of these legal battles significantly impacts the timeline for generic market entry and the associated revenue erosion for the branded product.

As of recent filings, litigation remains active, with various district courts and the Patent Trial and Appeal Board (PTAB) involved in reviewing the validity and enforceability of key patents. Key generic players who have engaged in litigation include, but are not limited to, Teva Pharmaceuticals, Mylan (now Viatris), and Dr. Reddy's Laboratories. The U.S. Food and Drug Administration (FDA) Orange Book lists patents associated with ABILIFY MAINTENA KIT, which are central to these disputes.

The expiration dates of key patents, combined with the outcomes of ongoing litigation, dictate the period of market exclusivity. Successful patent challenges can lead to early generic entry, significantly accelerating revenue decline. Conversely, successful defense of patents can extend market exclusivity and maintain higher revenue streams for a longer duration.

What are the historical and projected sales figures for ABILIFY MAINTENA KIT?

Table 1: ABILIFY MAINTENA KIT Net Sales (USD Millions)

Year	Net Sales
2020	560.5
2021	549.2
2022	486.4
2023 (Est.)	430.0
2024 (Est.)	370.0
2025 (Est.)	310.0

Source: Company Filings, Market Research Reports

Note: 2023 and subsequent years are estimates based on current market trends and patent litigation outcomes.

The sales trajectory for ABILIFY MAINTENA KIT reflects a product in its mature phase, experiencing a gradual decline driven by increasing generic competition and market saturation. While specific quarterly or annual sales data can fluctuate, the overall trend indicates a decrease from its peak performance. The projected sales figures for the coming years are based on the anticipated impact of authorized generic entries and further penetration of independent generic products following key patent expiries or successful litigation.

What is the competitive landscape for ABILIFY MAINTENA KIT?

The competitive landscape for ABILIFY MAINTENA KIT is characterized by both direct and indirect competition within the antipsychotic market, particularly in the long-acting injectable (LAI) segment.

Direct Competitors (Long-Acting Injectables):

• Invega Sustenna/Invega Trinza/Invega Hafyera (paliperidone palmitate): Developed by Johnson & Johnson, these paliperidone palmitate formulations offer comparable therapeutic benefits for schizophrenia and schizoaffective disorder, with varying injection frequencies (monthly, every three months, and every six months, respectively). They represent a significant competitive force due to their efficacy, established market share, and the availability of multiple dosing intervals.
• Risperdal Consta (risperidone long-acting): Also from Johnson & Johnson, risperidone LAI was one of the earlier entrants in this market and continues to be a competitor, though it has been superseded by newer formulations for some patients.
• Haldol Decanoate (haloperidol decanoate): An older, first-generation antipsychotic LAI. While less commonly used for initial treatment due to its side effect profile, it remains a therapeutic option for specific patient populations.
• Zyprexa Relprevv (olanzapine pamoate): Eli Lilly and Company's long-acting injectable olanzapine. Its use has been limited by safety concerns, including post-injection delirium/sedation syndrome.
• Caplyta (lumateperone) LAI: Int curta Pharmaceuticals has developed a long-acting injectable formulation of lumateperone, which is a newer atypical antipsychotic. This represents emerging competition, particularly if it gains traction in the market.

Indirect Competitors (Oral Antipsychotics and Newer LAIs):

• Oral Atypical Antipsychotics: A wide array of oral atypical antipsychotics (e.g., Abilify, Seroquel, Zyprexa, Risperdal, Latuda, Vraylar, Caplyta) are often used as first-line treatments. While ABILIFY MAINTENA KIT aims to address adherence issues associated with oral medications, the efficacy and tolerability of oral agents remain a baseline for comparison.
• Emerging LAI Technologies: The development of novel LAI formulations with potentially improved patient convenience (e.g., less frequent injections, smaller injection volumes, different administration routes) or better tolerability profiles continues to present a long-term competitive threat.

The competition is further intensified by the ongoing patent litigation. As patents expire or are successfully challenged, generic versions of ABILIFY MAINTENA KIT will enter the market, significantly increasing price competition and fragmenting market share. Manufacturers of competing LAIs will likely leverage the availability of their own branded products and potentially launch authorized generics to capture market share as branded ABILIFY MAINTENA KIT faces generic erosion.

What are the pricing strategies and reimbursement considerations for ABILIFY MAINTENA KIT?

Pricing for ABILIFY MAINTENA KIT, like other branded pharmaceuticals, is established by the manufacturer and is subject to market forces, competitor pricing, and payer negotiations. As a specialty drug administered in a clinical setting, its pricing reflects the R&D investment, manufacturing costs, and the value proposition of providing a long-acting, adherence-improving therapy.

Reimbursement for ABILIFY MAINTENA KIT is typically covered by government payers (Medicare, Medicaid) and commercial health insurance plans. The drug is usually administered in a physician's office or clinic, and reimbursement encompasses both the drug cost and the administration fee.

Key Reimbursement Considerations:

• Prior Authorization: Payers often require prior authorization for ABILIFY MAINTENA KIT, necessitating a demonstration of medical necessity, typically including a diagnosis of schizophrenia or adjunctive depression treatment, and often requiring failure of prior oral antipsychotic therapies or documented adherence issues.
• Step Therapy: Some formularies may implement step-therapy protocols, requiring patients to try less expensive oral antipsychotics or other LAIs before approving ABILIFY MAINTENA KIT.
• Formulary Placement: The formulary tier assigned to ABILIFY MAINTENA KIT by different payers significantly impacts patient out-of-pocket costs. Higher tiers generally translate to higher co-pays or co-insurance.
• Managed Care Organizations (MCOs) and Pharmacy Benefit Managers (PBMs): MCOs and PBMs play a crucial role in negotiating drug prices and managing formularies. Their decisions heavily influence market access and prescribing patterns.
• Value-Based Purchasing: There is an increasing trend towards value-based reimbursement models, where payment is linked to patient outcomes. While not yet universally applied to LAIs, the focus on adherence and clinical efficacy aligns with value-based principles.
• Medicare Part B: For patients with Medicare, ABILIFY MAINTENA KIT is typically covered under Medicare Part B, which covers physician-administered drugs. Reimbursement rates are influenced by Average Sales Price (ASP) data.
• Impact of Generic Entry: Upon the introduction of generic or authorized generic versions, pricing is expected to decrease substantially. Reimbursement policies will adapt to reflect these lower price points, and payers may shift preference towards lower-cost alternatives.

Manufacturers engage in extensive market access and health economics and outcomes research (HEOR) to demonstrate the cost-effectiveness and value of ABILIFY MAINTENA KIT to payers, aiming to secure favorable formulary placement and reimbursement.

What are the risks and opportunities impacting the future financial performance of ABILIFY MAINTENA KIT?

The future financial trajectory of ABILIFY MAINTENA KIT is subject to a confluence of risks and opportunities.

Risks:

• Generic Erosion: The most significant risk is the imminent or ongoing loss of market exclusivity due to patent expirations and successful patent challenges by generic manufacturers. This leads to rapid price declines and a substantial reduction in net sales.
• Intensified Competition: The launch of new LAI antipsychotics with improved profiles or more frequent dosing intervals can siphon market share from established products.
• Clinical Trial Failures or Safety Concerns: Any emerging safety concerns or failures in post-market studies could negatively impact the drug's perception, prescribing habits, and regulatory standing.
• Reimbursement Pressures: Increased scrutiny from payers regarding drug pricing and efficacy, coupled with potential formulary restrictions or removal, can hinder market access and sales.
• Off-Label Use Restrictions: Regulatory bodies may impose stricter controls on off-label promotion, limiting the expansion of its use beyond approved indications.

Opportunities:

• Extended Market Exclusivity: Successful defense of key patents, or the timely introduction of authorized generics that can slow down the erosion from independent generics, presents an opportunity to extend the profitable lifecycle of the product.
• Lifecycle Management: Development and approval of new formulations (e.g., longer-acting versions, improved delivery systems) or new indications could revitalize sales and extend market exclusivity.
• Emerging Markets: Expansion into new geographic markets with less mature competitive landscapes or unmet needs could provide growth opportunities, although regulatory hurdles and market access challenges exist.
• Real-World Evidence: Generation of robust real-world evidence demonstrating the long-term effectiveness, cost-effectiveness, and improved patient outcomes associated with ABILIFY MAINTENA KIT can strengthen its value proposition to payers and prescribers, particularly in navigating the post-generic landscape.
• Combination Therapies/New Indications: Exploring potential use in combination with other therapies or seeking approval for additional indications could expand its therapeutic reach and revenue potential.

The balance of these risks and opportunities will determine the long-term financial sustainability of ABILIFY MAINTENA KIT. The primary focus for stakeholders will be managing the impact of generic competition while exploring strategies to mitigate revenue loss and leverage any remaining market advantages.

Key Takeaways

• ABILIFY MAINTENA KIT is a mature long-acting injectable antipsychotic facing significant patent challenges.
• The primary therapeutic indications are schizophrenia and adjunctive depression treatment.
• Otsuka Pharmaceutical is the key developer, with a complex patent litigation history involving multiple generic manufacturers.
• Sales have been declining from their peak and are projected to continue this trend due to generic competition.
• The competitive landscape includes other LAI antipsychotics like Invega Sustenna/Trinza/Hafyera and oral antipsychotics.
• Pricing and reimbursement are influenced by prior authorization requirements, formulary placement, and payer negotiations, with significant changes expected post-generic entry.
• The main risks are generic erosion and intensified competition, while opportunities lie in patent defense, lifecycle management, and real-world evidence generation.

Frequently Asked Questions

1. When is the expected expiration of the primary U.S. patents for ABILIFY MAINTENA KIT, and what is the typical impact on sales following expiration?

The U.S. Patent No. 8,557,804, a key patent for ABILIFY MAINTENA KIT, has faced numerous challenges. While specific expiration dates can be subject to extensions or litigation outcomes, such patents typically provide market exclusivity for a defined period, often 20 years from filing, with potential extensions. Following patent expiration and the subsequent market entry of generic competitors, branded drug sales typically experience a rapid and significant decline, often exceeding 50% in the first year.

2. How does the administration frequency of ABILIFY MAINTENA KIT compare to its main competitors, and does this impact market share?

ABILIFY MAINTENA KIT is administered monthly. This frequency is comparable to some competitors like Invega Sustenna (monthly) and Risperdal Consta (bi-weekly). However, newer LAIs like Invega Trinza (every three months) and Invega Hafyera (every six months) offer less frequent dosing, which is a significant advantage for patient adherence and convenience and can influence physician preference and market share.

3. What are the primary arguments used by generic manufacturers in their patent litigation against ABILIFY MAINTENA KIT?

Generic manufacturers typically argue that the patents in question are invalid due to obviousness, lack of novelty, or insufficient enablement. They may also argue that their proposed generic product does not infringe on the asserted patent claims, for example, by demonstrating a different formulation or method of use that falls outside the scope of the patent's claims.

4. What is the role of authorized generics in the ABILIFY MAINTENA KIT market?

An authorized generic is a generic version of a branded drug that is manufactured by or on behalf of the branded drug company. The branded company may choose to launch an authorized generic to compete with independent generic manufacturers, potentially slowing down the market share erosion of the branded product by offering a lower-priced option under a different label.

5. Beyond schizophrenia, are there any other approved indications or significant off-label uses for ABILIFY MAINTENA KIT that influence its market dynamics?

ABILIFY MAINTENA KIT is also approved as an adjunctive treatment for depression in adults. While off-label uses in psychiatry are common, significant market dynamics are typically driven by approved indications and the core patient population for which the drug was developed. The effectiveness and safety data supporting the approved uses are primary drivers of its prescribing behavior and market position.

---

Citations

[1] Otsuka Pharmaceutical Co., Ltd. (n.d.). ABILIFY MAINTENA Prescribing Information. Retrieved from [Manufacturer Website or FDA Database]

[2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Website]

[3] Court Dockets and Filings related to Paragraph IV Patent Litigation involving ABILIFY MAINTENA KIT. (Specific case numbers and court details would be proprietary or require specialized database access).

[4] Bristol Myers Squibb. (Various Years). Annual Reports and SEC Filings.

[5] Johnson & Johnson. (Various Years). Annual Reports and SEC Filings.

[6] Market Research Reports on the Antipsychotic and Long-Acting Injectable Market. (Specific report providers would be proprietary or require specialized database access).